For research use only. Not for therapeutic Use.
Omalizumab(Cat No.:I044213)is a recombinant humanized monoclonal antibody that targets immunoglobulin E (IgE). By binding to free IgE, omalizumab prevents its interaction with IgE receptors on mast cells and basophils, thereby inhibiting the allergic cascade. It is approved for the treatment of moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria, and nasal polyps. Administered subcutaneously, omalizumab reduces the frequency and severity of allergic reactions, improving patient quality of life. Its targeted mechanism offers an effective option for patients with refractory allergic conditions not adequately controlled by standard therapies.
CAS Number | 242138-07-4 |
Purity | ≥95% |
Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |